Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Intragonadal Regulatory Protein, Mullerian Inhibiting Substance, Inhibin, Epidermal Growth Factor, Nerve Growth Factor, Dopamine, Norepinephrine, Etc.) Patents (Class 530/388.24)
  • Patent number: 11370820
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 28, 2022
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 11267902
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: March 8, 2022
    Inventors: Nazer Khalaf, Saraswathi Mandapati, Reena J. Patel
  • Patent number: 11208482
    Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 28, 2021
    Assignee: FORTY SEVEN, INC.
    Inventors: Jie Liu, Kavitha Sompalli
  • Patent number: 10961305
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 30, 2021
    Assignee: MEREO BIOPHARMA 3 LIMITED
    Inventors: Uwe Junker, Michaela Kneissel, Anthony Kent Hall, Rena Joy Eudy, Matthew Manning Riggs
  • Patent number: 10562964
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: February 18, 2020
    Assignee: AMGEN INC.
    Inventor: Christopher J. Paszty
  • Patent number: 9541563
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: January 10, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • Patent number: 9133272
    Abstract: The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: September 15, 2015
    Assignee: AMGEN INC.
    Inventors: Monica Florio, Taruna Arora, Christopher J. R. Paszty, William G. Richards
  • Patent number: 9127051
    Abstract: The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: September 8, 2015
    Assignee: Queen Mary & Westfield College, University of London
    Inventors: Fulvio D'Acquisto, Mauro Perretti
  • Patent number: 9076324
    Abstract: A remote control system includes an in-vehicle controller that is installed in a vehicle and controls in-vehicle devices installed in the vehicle; a mobile communication device that remotely controls the in-vehicle devices via the in-vehicle controller; and a wireless communication device that is installed in the vehicle and intervenes and establishes wireless communication between the in-vehicle controller and the mobile communication device, wherein the wireless communication device includes a reception-mode switching unit that switches between a reception standby mode with consumption of a standby current to prepare for reception from the mobile communication device and a reception dormant mode without consumption of a standby current in accordance with a time schedule.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: July 7, 2015
    Assignee: MITSUBISHI JIDOSHA KOGYO KABUSHIKI KAISHA
    Inventors: Hiroyuki Yashiro, Naoki Kawashima, Hiroki Fukatsu, Takuma Maeda, Masahide Shiba
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Publication number: 20150118156
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 30, 2015
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Patent number: 9018163
    Abstract: This invention relates to PCIFl and its use as a target for the improvement of pancreatic islet ? cell mass and function in diabetes. Specifically, the invention relates to the use of compounds capable of modulating the expression or function of PClFl and their effect on the function of Pdx-1.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: April 28, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Doris Stoffers
  • Publication number: 20150110776
    Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: April 23, 2015
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Publication number: 20150110787
    Abstract: A polypeptide, antagonist, and antibody that specifically bind to and inhibit VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 23, 2015
    Inventors: Seok Kyun KIM, Sang Yeul HAN, Kwang Hoon LEE, Kyung Eun KIM
  • Patent number: 9012610
    Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 21, 2015
    Assignee: Hytest Ltd.
    Inventors: Alexey G. Katrukha, Alexander B. Postnikov, Tatiana I. Solovyeva, Alexey V. Kharitonov
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Patent number: 8999331
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: April 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • Patent number: 8999936
    Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 7, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Patent number: 8992911
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: March 31, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Patent number: 8992925
    Abstract: Chimeric molecules comprising receptor activator of NF-?B ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: March 31, 2015
    Assignee: Amgen Inc.
    Inventors: Paul Kostenuik, Wenyan Shen, Thomas C. Boone
  • Patent number: 8986952
    Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 24, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
  • Patent number: 8987421
    Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: March 24, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
  • Patent number: 8987420
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: March 24, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gavin Thurston, Christopher Daly
  • Patent number: 8975381
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 10, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Patent number: 8962257
    Abstract: The invention relates to methods of diagnosing the severity of heart failure or a cardiac dysfunction in a subject. The invention further relates to monitoring the severity of heart failure in a subject and determining the prognosis of a subject that has suffered from heart failure. This invention also relates methods to identify patients at risk for cardiac dysfunction when exposed to cardiotoxic chemotherapy agents.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: February 24, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Bonnie Ky, Thomas Cappola, Douglas B. Sawyer
  • Patent number: 8940874
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 27, 2015
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • Patent number: 8940305
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 27, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Publication number: 20150025226
    Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.
    Type: Application
    Filed: October 7, 2014
    Publication date: January 22, 2015
    Inventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
  • Patent number: 8932591
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 13, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8926978
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 6, 2015
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • Patent number: 8916158
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8916157
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8911741
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 16, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8907067
    Abstract: This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: December 9, 2014
    Assignee: Oscient Pharmaceuticals Corporation
    Inventors: Tim Keith, Randall D. Little, Paul Van Eerdewegh, Josée Dupuis, Richard G. Del Mastro, Jason Simon, Kristina Allen, Sunil D. Pandit
  • Patent number: 8900817
    Abstract: Progastrin levels are determined to diagnose one or more liver pathologies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 2, 2014
    Assignee: Les Laboratories Servier
    Inventors: Jean-François Floch, Leïla Houhou
  • Patent number: 8883976
    Abstract: An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Hendrik Knoetgen, Jens Niewoehner
  • Patent number: 8883724
    Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: November 11, 2014
    Assignee: Centro de Ingenieria Genética y Biotecnologia
    Inventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
  • Patent number: 8871518
    Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: October 28, 2014
    Assignees: Otsuka Pharmaceutical Co., Ltd., LSI Medience Corporation
    Inventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
  • Patent number: 8858941
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 14, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Publication number: 20140288278
    Abstract: Disclosed are methods and processes utilizing multi-modal chromatography as a polishing step to separate heterogeneously charged (basic and acidic) aggregates and other impurities from partially a partially purified bulk product monoclonal antibody product. The resulting chromatographic process provides a scaleable production process that is cost effective and increases the productivity of the purification process over a platform utilizing a combination of anion and cation exchange chromatography to resolve heterogeneous aggregates.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 25, 2014
    Inventors: Joseph Nti-gyabaah, Sandra Meissner, Rebecca Chmielowski, Janelle Konietzko
  • Patent number: 8840886
    Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: September 23, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
  • Publication number: 20140271646
    Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 18, 2014
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
  • Patent number: 8834879
    Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 16, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Patent number: 8834883
    Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: September 16, 2014
    Assignee: Vaccinex, Inc.
    Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
  • Patent number: 8828382
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: September 9, 2014
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
  • Patent number: 8828386
    Abstract: A method lessening intraventricular hemorrhage in the fetus of a gravid human patient is provided where the patient is administered a therapeutically effective amount of digoxin antibody.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: September 9, 2014
    Assignees: Glenveigh Pharmaceuticals, LLC, CDA Royalty Investors, LLC
    Inventor: Charles David Adair
  • Patent number: 8822644
    Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: September 2, 2014
    Assignee: Zenyth Operations Pty Ltd
    Inventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
  • Patent number: 8809507
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: August 19, 2014
    Inventor: Vuong Trieu
  • Patent number: 8802102
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: RE47982
    Abstract: The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 12, 2020
    Assignee: Queen Mary & Westfield College, University of London
    Inventors: Fulvio D'Acquisto, Mauro Perretti